I am a mission-driven drug developer and former academic expert in pulmonary fibrosis and lung transplantation. I build and manage best-in-bred teams to develop transformative therapeutics to improve the lives of patients living with respiratory, fibrotic, immunological, and inflammatory diseases. I define innovative strategies to move a portfolio of drug candidates into early- and late-stage development and global registration, through to commercialization. I define and execute clinical development plans, including study design, protocol development, data analysis and interpretation, ensuring studies align with corporate and R&D objectives, are scientifically sound, uphold high ethical standards, and protect the safety of patients.

I possess an extensive background in clinical research. I led NIH funded clinical and epidemiological research studies in interstitial lung disease and lung transplantation. As a key opinion leader in IPF, I participated in numerous clinical trial steering committees. I am a former standing member on the FDA Pulmonary-Allergy Drug Advisory Committee. I have authored 200+ peer-reviewed publications.